Adenocarcinoma transformed into squamous cell carcinoma in non-small cell lung cancer

Yueqiang Jiang; Jun Zhang; Jin Feng; Yaping Lu; Yuan Fan; Ling Cheng; Xin Liao; Liya Hu; Shiying Yu; Tiejun Yin

doi:10.1016/j.jgg.2021.07.002

Volume 48 Issue 7

Jul. 2021

Turn off MathJax

Article Contents

Article Navigation > Journal of Genetics and Genomics > 2021 > 48(7): 656-659

PDF( 1040 KB)

Adenocarcinoma transformed into squamous cell carcinoma in non-small cell lung cancer

doi: 10.1016/j.jgg.2021.07.002

a Department of Geriatrics, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China;
b Sinopharm Genomics Technology Co., LTD, Block B3, No.9, Changyang Road, West Taihu Lake Science and Technology Industrial Zone, Changzhou, Jiangsu 213000, China;
c Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China

Funds:

We thank the three patients and their relatives for approving the inclusion of their data and information in this study. We also thank Xudong Jiang for the discussion and the anonymous reviewers for their insightful and helpful comments on this work.

Received Date: 2021-05-12
Publish Date: 2021-07-20

Abstract

FullText(HTML)

References(20)

References

Ahn, M.J., Sun, J.M., Lee, S.H., Ahn, J.S., Park, K., 2017. EGFR TKI combination with immunotherapy in non-small cell lung cancer. Expert Opin. Drug Saf. 16, 465-469.

Casulo, C., Burack, W.R., Friedberg, J.W., 2015. Transformed follicular non-hodgkin lymphoma. Blood 125, 40-47.

Chen, D., Ning, Z., Chen, H., Lu, C., Liu, X., Xia, T., Qi, H., Wang, W., Ling, T., Guo, X., et al., 2020. An integrative pan-cancer analysis of biological and clinical impacts underlying ubiquitin-specific-processing proteases. Oncogene 39, 587-602.

Chen, Y., Tang, W.Y., Tong, X., Ji, H., 2019. Pathological transition as the arising mechanism for drug resistance in lung cancer. Canc. Commun. 39, 53.

Chen, Y., Xue, Y., Jin, Y., Ji, H., 2021. Lung stem cells in regeneration and tumorigenesis. J. Genet. Genom. 48, 268-276.

Han, X., Li, F., Fang, Z., Gao, Y., Li, F., Fang, R., Yao, S., Sun, Y., Li, L., Zhang, W., et al., 2014. Transdifferentiation of lung adenocarcinoma in mice with Lkb1 deficiency to squamous cell carcinoma. Nat. Commun. 5, 3261.

Hanna, N., Johnson, D., Temin, S., Baker Jr., S., Brahmer, J., Ellis, P.M., Giaccone, G., Hesketh, P.J., Jaiyesimi, I., Leighl, N.B., et al., 2017. Systemic therapy for stage IV non-small-cell lung cancer:American Society of Clinical Oncology clinical practice guideline update. J. Clin. Oncol. 35, 3484-3515.

Hou, S., Han, X., Ji, H., 2016. Squamous transition of lung adenocarcinoma and drug resistance. Trends Cancer 2, 463-466.

Izumi, H., Yamasaki, A., Ueda, Y., Sumikawa, T., Maeta, H., Nakamoto, S., Shimizu, E., 2018. Squamous cell carcinoma transformation from EGFR-mutated lung adenocarcinoma:a case report and literature review. Clin. Lung Cancer 19, e63-e66.

Li, F., Han, X., Li, F., Wang, R., Wang, H., Gao, Y., Wang, X., Fang, Z., Zhang, W., Yao, S., et al., 2015. LKB1 inactivation elicits a redox imbalance to modulate non-small cell lung cancer plasticity and therapeutic response. Cancer Cell 27, 698-711.

Lin, G., Li, C., Li, P.S., Fang, W.Z., Xu, H.P., Gong, Y.H., Zhu, Z.F., Hu, Y., Liang, W.H., Chu, Q., et al., 2020. Genomic origin and EGFR-TKI treatments of pulmonary adenosquamous carcinoma. Ann. Oncol. 31, 517-524.

Niederst, M.J., Sequist, L.V., Poirier, J.T., Mermel, C.H., Lockerman, E.L., Garcia, A.R., Katayama, R., Costa, C., Ross, K.N., Moran, T., et al., 2015. RB loss in resistant EGFR mutant lung adenocarcinomas that transform to smallcell lung cancer. Nat. Commun. 6, 6377.

Ried, T., Meijer, G.A., Harrison, D.J., Grech, G., Franch-Exposito, S., Briffa, R., Carvalho, B., Camps, J., 2019. The landscape of genomic copy number alterations in colorectal cancer and their consequences on gene expression levels and disease outcome. Mol. Aspect. Med. 69, 48-61.

Schoenfeld, A.J., Chan, J.M., Kubota, D., Sato, H., Rizvi, H., Daneshbod, Y., Chang, J.C., Paik, P.K., Offin, M., Arcila, M.E., et al., 2020. Tumor analyses reveal squamous transformation and off-target alterations as early resistance mechanisms to first-line osimertinib in EGFR-mutant lung cancer. Clin. Cancer Res. 26, 2654-2663.

Shukuya, T., Takahashi, T., Kaira, R., Ono, A., Nakamura, Y., Tsuya, A., Kenmotsu, H., Naito, T., Kaira, K., Murakami, H., et al., 2011. Efficacy of gefitinib for nonadenocarcinoma non-small-cell lung cancer patients harboring epidermal growth factor receptor mutations:a pooled analysis of published reports. Cancer Sci. 102, 1032-1037.

Siegel, R.L., Miller, K.D., Jemal, A., 2019. Cancer statistics, 2019. Cancer J. Clin. 69, 7-34.

Soria, J.C., Ohe, Y., Vansteenkiste, J., Reungwetwattana, T., Chewaskulyong, B., Lee, K.H., Dechaphunkul, A., Imamura, F., Nogami, N., Kurata, T., et al., 2018. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N. Engl. J. Med. 378, 113-125.

Swanton, C., Govindan, R., 2016. Clinical implications of genomic discoveries in lung cancer. N. Engl. J. Med. 374, 1864-1873.

Xu, C., Fillmore, C.M., Koyama, S., Wu, H., Zhao, Y., Chen, Z., Herter-Sprie, G.S., Akbay, E.A., Tchaicha, J.H., Altabef, A., et al., 2014. Loss of Lkb1 and Pten leads to lung squamous cell carcinoma with elevated PD-L1 expression. Cancer Cell 25, 590-604.

Yu, H.A., Arcila, M.E., Rekhtman, N., Sima, C.S., Zakowski, M.F., Pao, W., Kris, M.G., Miller, V.A., Ladanyi, M., Riely, G.J., 2013. Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFRmutant lung cancers. Clin. Cancer Res. 19, 2240-2247.

Relative Articles

Supplements(0)

Cited By

Proportional views